Kontafarma China Holdings Past Earnings Performance
Past criteria checks 0/6
Kontafarma China Holdings's earnings have been declining at an average annual rate of -38.5%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 15.3% per year.
Key information
-38.5%
Earnings growth rate
-38.5%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | -15.3% |
Return on equity | -5.8% |
Net Margin | -3.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?
Dec 28Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Sep 01Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Dec 29Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?
Sep 15Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?
Apr 20Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?
Nov 04Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares
Feb 18These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively
Dec 07Revenue & Expenses BreakdownBeta
How Kontafarma China Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 809 | -29 | 542 | 0 |
30 Sep 23 | 841 | -12 | 540 | 0 |
30 Jun 23 | 874 | 5 | 536 | 0 |
31 Mar 23 | 884 | -40 | 549 | 0 |
31 Dec 22 | 894 | -85 | 562 | 0 |
30 Sep 22 | 997 | -24 | 575 | 0 |
30 Jun 22 | 869 | -10 | 536 | 0 |
31 Mar 22 | 836 | -29 | 498 | 0 |
31 Dec 21 | 803 | -48 | 460 | 0 |
30 Jun 21 | 938 | -119 | 509 | 0 |
31 Mar 21 | 974 | -81 | 508 | 0 |
31 Dec 20 | 1,009 | -42 | 508 | 0 |
30 Jun 20 | 661 | 66 | 473 | 0 |
31 Mar 20 | 791 | 60 | 467 | 0 |
31 Dec 19 | 921 | 54 | 460 | 0 |
30 Sep 19 | 1,280 | 29 | 459 | 0 |
30 Jun 19 | 1,666 | 22 | 428 | 0 |
31 Mar 19 | 1,880 | 27 | 414 | 0 |
31 Dec 18 | 2,094 | 32 | 400 | 0 |
30 Sep 18 | 1,985 | 12 | 370 | 0 |
30 Jun 18 | 1,876 | -8 | 340 | 0 |
31 Mar 18 | 1,610 | -5 | 306 | 0 |
31 Dec 17 | 1,344 | -2 | 272 | 0 |
30 Sep 17 | 1,175 | -15 | 243 | 0 |
30 Jun 17 | 1,006 | -27 | 213 | 0 |
31 Mar 17 | 820 | -32 | 172 | 0 |
31 Dec 16 | 633 | -37 | 131 | 0 |
30 Sep 16 | 539 | -43 | 95 | 0 |
30 Jun 16 | 445 | -49 | 60 | 0 |
31 Mar 16 | 456 | -41 | 62 | 0 |
31 Dec 15 | 466 | -34 | 65 | 0 |
30 Sep 15 | 547 | -18 | 65 | 0 |
30 Jun 15 | 628 | -2 | 65 | 0 |
31 Mar 15 | 681 | 8 | 60 | 0 |
31 Dec 14 | 733 | 17 | 55 | 0 |
30 Sep 14 | 747 | 28 | 52 | 0 |
30 Jun 14 | 761 | 38 | 49 | 0 |
31 Mar 14 | 732 | 35 | 48 | 0 |
31 Dec 13 | 703 | 33 | 47 | 0 |
30 Sep 13 | 685 | 27 | 58 | 0 |
30 Jun 13 | 667 | 22 | 69 | 0 |
Quality Earnings: 1312 is currently unprofitable.
Growing Profit Margin: 1312 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1312 is unprofitable, and losses have increased over the past 5 years at a rate of 38.5% per year.
Accelerating Growth: Unable to compare 1312's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1312 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.3%).
Return on Equity
High ROE: 1312 has a negative Return on Equity (-5.76%), as it is currently unprofitable.